EOS lentiviral vector selection system for human induced pluripotent stem cells - PubMed (original) (raw)
EOS lentiviral vector selection system for human induced pluripotent stem cells
Akitsu Hotta et al. Nat Protoc. 2009.
Abstract
Generation of induced pluripotent stem (iPS) cells from patients has exciting applications for studying molecular mechanisms of diseases, screening drugs and ultimately for use in cell therapies. However, the low efficiency and heterogeneous nature of reprogramming is a major impediment to the generation of personalized iPS cell lines. We reported in Nature Methods (6, 370-376, 2009) the first selection system to enrich for reprogrammed human iPS cells. Using a lentiviral vector that specifically expresses the enhanced green fluorescence protein and puromycin resistance genes in pluripotent stem cells, it is now possible to mark and enrich for human iPS cell colonies expressing endogenous pluripotency markers. In this study, we describe a detailed protocol for the production of the pluripotent state-specific lentiviral vector and the selection system for the induction of healthy and disease-specific human iPS cells. Overall, preparation of the selection system takes 2 weeks, and the generation of human iPS cells takes approximately 2 months.
Similar articles
- Isolation of human iPS cells using EOS lentiviral vectors to select for pluripotency.
Hotta A, Cheung AY, Farra N, Vijayaragavan K, Séguin CA, Draper JS, Pasceri P, Maksakova IA, Mager DL, Rossant J, Bhatia M, Ellis J. Hotta A, et al. Nat Methods. 2009 May;6(5):370-6. doi: 10.1038/nmeth.1325. Epub 2009 Apr 26. Nat Methods. 2009. PMID: 19404254 - Generation of Mouse-Induced Pluripotent Stem Cells by Lentiviral Transduction.
Liu X, Chen J, Firas J, Paynter JM, Nefzger CM, Polo JM. Liu X, et al. Methods Mol Biol. 2019;1940:63-76. doi: 10.1007/978-1-4939-9086-3_5. Methods Mol Biol. 2019. PMID: 30788818 - Antibody-directed lentiviral gene transduction for live-cell monitoring and selection of human iPS and hES cells.
Wu DT, Seita Y, Zhang X, Lu CW, Roth MJ. Wu DT, et al. PLoS One. 2012;7(4):e34778. doi: 10.1371/journal.pone.0034778. Epub 2012 Apr 20. PLoS One. 2012. PMID: 22536330 Free PMC article. - Advancements in reprogramming strategies for the generation of induced pluripotent stem cells.
Lai MI, Wendy-Yeo WY, Ramasamy R, Nordin N, Rosli R, Veerakumarasivam A, Abdullah S. Lai MI, et al. J Assist Reprod Genet. 2011 Apr;28(4):291-301. doi: 10.1007/s10815-011-9552-6. Epub 2011 Mar 9. J Assist Reprod Genet. 2011. PMID: 21384252 Free PMC article. Review. - Retroviral vector silencing during iPS cell induction: an epigenetic beacon that signals distinct pluripotent states.
Hotta A, Ellis J. Hotta A, et al. J Cell Biochem. 2008 Nov 1;105(4):940-8. doi: 10.1002/jcb.21912. J Cell Biochem. 2008. PMID: 18773452 Review.
Cited by
- Three-dimensional growth of iPS cell-derived smooth muscle cells on nanofibrous scaffolds.
Xie C, Hu J, Ma H, Zhang J, Chang LJ, Chen YE, Ma PX. Xie C, et al. Biomaterials. 2011 Jul;32(19):4369-75. doi: 10.1016/j.biomaterials.2011.02.049. Epub 2011 Mar 24. Biomaterials. 2011. PMID: 21439638 Free PMC article. - Inhibiting ubiquitin conjugating enzyme E2 N by microRNA-590-3p reduced cell growth of cervical carcinoma.
Song TT, Xu F, Wang W. Song TT, et al. Kaohsiung J Med Sci. 2020 Jul;36(7):501-507. doi: 10.1002/kjm2.12204. Epub 2020 Mar 20. Kaohsiung J Med Sci. 2020. PMID: 32196955 Free PMC article. - Fyn Kinase regulates GluN2B subunit-dominant NMDA receptors in human induced pluripotent stem cell-derived neurons.
Zhang WB, Ross PJ, Tu Y, Wang Y, Beggs S, Sengar AS, Ellis J, Salter MW. Zhang WB, et al. Sci Rep. 2016 Apr 4;6:23837. doi: 10.1038/srep23837. Sci Rep. 2016. PMID: 27040756 Free PMC article. - JNK signaling provides a novel therapeutic target for Rett syndrome.
Musi CA, Castaldo AM, Valsecchi AE, Cimini S, Morello N, Pizzo R, Renieri A, Meloni I, Bonati M, Giustetto M, Borsello T. Musi CA, et al. BMC Biol. 2021 Dec 16;19(1):256. doi: 10.1186/s12915-021-01190-2. BMC Biol. 2021. PMID: 34911542 Free PMC article. - Identification of drug candidate against prostate cancer from the aspect of somatic cell reprogramming.
Kosaka T, Nagamatsu G, Saito S, Oya M, Suda T, Horimoto K. Kosaka T, et al. Cancer Sci. 2013 Aug;104(8):1017-26. doi: 10.1111/cas.12183. Epub 2013 May 26. Cancer Sci. 2013. PMID: 23600803 Free PMC article.
References
- J Cell Biochem. 2008 Nov 1;105(4):940-8 - PubMed
- Nat Protoc. 2006;1(4):2082-7 - PubMed
- Nature. 2008 Jan 10;451(7175):141-6 - PubMed
- Curr Protoc Mol Biol. 2005 Aug;Chapter 28:Unit 28.3 - PubMed
- Nat Protoc. 2008;3(7):1180-6 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- IG1-94505/Canadian Institutes of Health Research/Canada
- MOP-186015/Canadian Institutes of Health Research/Canada
- MOP-81129/Canadian Institutes of Health Research/Canada
- RMF-92090/Canadian Institutes of Health Research/Canada
LinkOut - more resources
Full Text Sources
Research Materials